For Researchers
E. Marzetti, R. Calvani, M. Tosato, et al.Aging Clin Exp Res Epub 2017 Feb 10 CLICK HERE TO READ THE FULL TEXT The present review summarizes the available evidence in support of physical activity as a remedy against physical frailty and sarcopenia. |
R. Le Lain, C. Ignaszewski, I. Klingmann, et al.Aging Clin Exp Res Epub 2017 Feb 10 CLICK HERE TO READ THE FULL TEXT The present article describes the SPRINTT workpackage activities aimed at engaging the scientific discussion on the physical frailty and sarcopenia with the EMA as one of its interlocutor acknowledging the need to collaborate on this topic to foster a productive dialogue. |
R. Bernabei, L. Mariotti, P. Bordes, et al.Aging Clin Exp Res Epub 2017 Feb 10 CLICK HERE TO READ THE FULL TEXT The absolute and relative number of people aged 65+ is on a sharp rise worldwide. Such a demographic transition is certainly a desirable result of the magnificent combination of socioeconomic development, technological, and medical advancements, and the establishment of solid public health systems. |
R. Calvani, F. Marini, M. Cesari, et al.Aging Clin Exp Res Epub 2017 Feb 10 CLICK HERE TO READ THE FULL TEXT This review provides an overview of currently available biological markers for PF and sarcopenia, as well as a critical appraisal of strengths and weaknesses of traditional procedures for biomarker development in the field. A novel approach for biomarker identification and validation, based on multivariate methodologies, is also discussed.
|
A. J. Cruz-Jentoft, E. Kiesswetter, M. Drey, et al.Aging Clin Exp Res Epub 2017 Feb 10 CLICK HERE TO READ THE FULL TEXT This brief review explores the role of energy and protein intake and other key nutrients on muscle function. |
S. Del Signore and R.RoubenffAging Clin Exp Res Epub 2017 Feb 10 CLICK HERE TO READ THE FULL TEXT We agree with regulators that better characterization of subpopulations, not only in elderly patients, can improve the benefit risk ratio of medicines. At the same time, we believe it is in the public health interest to develop novel drugs indicated for specific geriatric conditions. |